The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Biochemistry,Physiology
Link
https://link.springer.com/content/pdf/10.1007/s13105-023-00974-0.pdf
Reference44 articles.
1. Alloza I, Goikuria H, Freijo MDM, Vandenbroeck K (2016) A role for autophagy in carotid atherosclerosis. Eur Stroke J 1(4):255–263. https://doi.org/10.1177/2396987316674085
2. Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B (2020) Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc 9(3):e014908. https://doi.org/10.1161/jaha.119.014908
3. Aviram M (2011) Atherosclerosis: cell biology and lipoproteins–inflammation and oxidative stress in atherogenesis: protective role for paraoxonases. Curr Opin Lipidol 22(3):243–4. https://doi.org/10.1097/MOL.0b013e3283474beb
4. Behnammanesh G, Durante GL, Khanna YP, Peyton KJ, Durante W (2020) Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: role of heme oxygenase-1. Redox Biol 32:101527. https://doi.org/10.1016/j.redox.2020.101527
5. Cai C, Guo Z, Chang X, Li Z, Wu F, He J, Cao T, Wang K, Shi N, Zhou H, Toan S, Muid D, Tan Y (2022) Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway. Redox Biol 52:102288. https://doi.org/10.1016/j.redox.2022.102288
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density;Current Opinion in Lipidology;2024-07-18
2. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications;Frontiers in Endocrinology;2024-04-05
3. Monocytic microRNAs—Novel targets in atherosclerosis therapy;British Journal of Pharmacology;2024-04-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3